Literature DB >> 27797248

Appropriate Timing of Surgery after Neoadjuvant ChemoRadiation Therapy for Locally Advanced Rectal Cancer.

Waheed Yousry Garrer1, Hisham Abd El Kader El Hossieny, Zeiad Samir Gad, Alfred Elias Namour, Sameh Mohammed Ahmed Abo Amer.   

Abstract

BACKGROUND: Surgery is the corner stone for the management of rectal cancer. The purpose of this study was to demonstrate the optimal time of surgical resection after the completion of neoadjuvant chemo-radiotherapy (CRT) in treatment of locally advanced rectal cancer.
MATERIALS AND METHODS: This study compared 2 groups of patients with locally advanced rectal cancer, treated with neoadjuvant CRT followed by surgical resection either 6-8 weeks or 9-14 weeks after the completion of chemo-radiotherapy. The impact of delaying surgery was tested in comparison to early surgical resection after completion of chemo-radiotherapy.
RESULTS: The total significant response rate that could result in functional preservation was estimated to be 3.85% in group I and 15.4% in group II. Some 9.62% of our patients had residual malignant cells at one cm surgical margin. All those patients with positive margins at one cm were in group I (19.23%). There was less operative time in group II, but the difference between both groups was statistically insignificant (P=0.845). The difference between both groups regarding operative blood loss and intra operative blood transfusion was significantly less in group II (P=0.044). There was no statistically significant difference between both groups regarding the intra operative complications (P=0.609). The current study showed significantly less post-operative hospital stay period, and less post-operative wound infection in group II (P=0.012 and 0.017). The current study showed more tumor regression and necrosis in group II with a highly significant main effect of time F=61.7 (P<0.001). Pathological TN stage indicated better pathological tumor response in group II (P=0.04). The current study showed recurrence free survival for all cases at 18 months of 84.2%. In group I, survival rate at the same duration was 73.8%, however none of group II cases had local recurrence (censored) (P=0.031). Disease free survival (DFS) during the same duration (18 months) was 69.4 % for patients in group I and 82.3% for group II (P=0.429).
CONCLUSIONS: Surgical resection delay up to 9-14 weeks after chemo-radiation was associated with better outcome and better recurrence free survival.

Entities:  

Mesh:

Year:  2016        PMID: 27797248

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  7 in total

1.  Does a long interval between neoadjuvant chemoradiotherapy and surgery benefit the clinical outcomes of locally advanced rectal cancer? A systematic review and meta analyses.

Authors:  Miao Yu; Deng-Chao Wang; Sheng Li; Li-Yan Huang; Jian Wei
Journal:  Int J Colorectal Dis       Date:  2022-03-12       Impact factor: 2.571

2.  Factors Predicting Pathological Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer: The Experience of a Single Institution with 269 Patients (STONE-01).

Authors:  Michele Fiore; Pasquale Trecca; Luca E Trodella; Roberto Coppola; Marco Caricato; Damiano Caputo; Alessandro Coppola; Gian M Petrianni; Gabriele D'Ercole; Edy Ippolito; Rolando M D'Angelillo; Sara Ramella
Journal:  Cancers (Basel)       Date:  2021-12-02       Impact factor: 6.639

3.  Temporal determinants of tumour response to neoadjuvant rectal radiotherapy.

Authors:  Kendrick Koo; Rachel Ward; Ryan L Smith; Jeremy Ruben; Peter W G Carne; Hany Elsaleh
Journal:  PLoS One       Date:  2021-06-30       Impact factor: 3.240

4.  Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes.

Authors:  Yi Liu; Ke-Cheng Zhang; Xiao-Hui Huang; Hong-Qing Xi; Yun-He Gao; Wen-Quan Liang; Xin-Xin Wang; Lin Chen
Journal:  World J Gastroenterol       Date:  2018-01-14       Impact factor: 5.742

5.  Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study.

Authors:  C Bisschop; T H van Dijk; J C Beukema; R L H Jansen; H Gelderblom; K P de Jong; H J T Rutten; C J H van de Velde; T Wiggers; K Havenga; G A P Hospers
Journal:  Ann Surg Oncol       Date:  2017-05-30       Impact factor: 5.344

6.  Factors predicting recurrence after curative resection for rectal cancer: a 16-year study.

Authors:  Waad Farhat; Mohamed Azzaza; Abdelkader Mizouni; Houssem Ammar; Mahdi Ben Ltaifa; Sami Lagha; Mohamed Kahloul; Rahul Gupta; Mohamed Ben Mabrouk; Ali Ben Ali
Journal:  World J Surg Oncol       Date:  2019-10-28       Impact factor: 2.754

7.  Is long interval from neoadjuvant chemoradiotherapy to surgery optimal for rectal cancer in the era of intensity-modulated radiotherapy?: a prospective observational study.

Authors:  Hui Chang; Wu Jiang; Wei-Jun Ye; Ya-Lan Tao; Qiao-Xuan Wang; Wei-Wei Xiao; Yuan-Hong Gao
Journal:  Onco Targets Ther       Date:  2018-09-21       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.